Americans Continue to Struggle to Access Branded GLP-1s as Shortages Continue
13 Novembre 2024 - 3:15PM
Business Wire
Hims & Hers introduces a GLP-1 Supply
Tracker to help more individuals advocate for accessible
healthcare
Hims & Hers Health, Inc. (“Hims & Hers”, NYSE: HIMS),
the leading health and wellness platform, today shared more data on
the challenges Americans are facing when trying to access branded
GLP-1 medication and introduced a GLP-1 Supply Tracker, where
individuals can be a part of advocating for better access to the
medications they need.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20241113063032/en/
Hims & Hers introduces a GLP-1 Supply
Tracker to help more individuals advocate for accessible
healthcare. (Graphic: Business Wire)
Hims & Hers has been collecting data on access challenges
across GLP-1s since the beginning of September. On just the Hims
& Hers platform alone, nearly 80,000 individuals have shared
they cannot access branded GLP-1 medications. Those numbers are
particularly pronounced in states where the obesity rate is higher.
For instance, in Texas, which is among the top 10 state obesity
rates in the country, nearly 5,000 Hims & Hers customers have
shared they cannot access the care they need. The company has been
actively communicating with state and federal legislative and
regulatory agencies to provide them with information about what
individuals on our platform have been experiencing.
In an effort to better understand the access challenges across
the US, Hims & Hers introduced the GLP-1 Supply Tracker to help
more individuals share their experiences and use their voice to
ensure the FDA has the information it needs to better support
accessible care. In just one week, nearly 7,000 individuals have
used the tracker to report that they cannot access their
medications, with brand name products containing semaglutide
reported as being the most challenging to access.
“Our customers have demonstrated a clear gap in supply and
demand, so we’re making it easy for everyone to share their
experience and be a part of advocating for better access to the
medications they need,” said Andrew Dudum, CEO and co-founder of
Hims & Hers. “Part of our responsibility to the millions of
customers who trust us with their healthcare is to understand the
scale of the challenges they face and use our platform to combat
them.”
Branded GLP-1 medications are challenging to access across the
country, with availability fluctuating up and down as drugmakers
invest in their ability to meet the immense amount of demand. While
no official report has quantified the reach and impact of the
shortage, research into Hims & Hers customers found that nearly
30% of Weight Loss customers who had been prescribed a branded
GLP-1 in the past were unable to fill it because the medication was
not available at their pharmacy. As more people become aware of
these medications and the stigma associated with seeking treatment
for obesity ebbs, this demand will continue to rise: Research from
the University of Southern California showed a 442% increase in
prescriptions for semaglutide between January 2021 and December
2023.
Consumers struggling to access the branded GLP-1 medications
they’ve been prescribed can visit
www.hims.com/weight-loss/supply-tracker or
www.forhers.com/weight-loss/supply-tracker to share more about
their experience.
About Hims & Hers Health, Inc
Hims & Hers is the leading health and wellness platform on a
mission to help the world feel great through the power of better
health. We believe how you feel in your body and mind transforms
how you show up in life. That’s why we’re building a future where
nothing stands in the way of harnessing this power. Hims & Hers
normalizes health & wellness challenges—and innovates on their
solutions—to make feeling happy and healthy easy to achieve. No two
people are the same, so the company provides access to personalized
care designed for results. For more information, please visit
www.hims.com and www.forhers.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20241113063032/en/
Press Contact Abby Reisinger press@forhims.com
Grafico Azioni Hims and Hers Health (NYSE:HIMS)
Storico
Da Nov 2024 a Dic 2024
Grafico Azioni Hims and Hers Health (NYSE:HIMS)
Storico
Da Dic 2023 a Dic 2024